首页> 外文期刊>Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy >Double Filtration Plasmapheresis in the Treatment of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis With Severe Renal Failure: A Preliminary Study of 15 Patients
【24h】

Double Filtration Plasmapheresis in the Treatment of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis With Severe Renal Failure: A Preliminary Study of 15 Patients

机译:双滤血浆置换术治疗抗中性粒细胞胞浆自身抗体相关性血管炎伴严重肾功能衰竭:15例患者的初步研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Our aim was to investigate the clinical efficacy of double filtration plasmapheresis (DFPP) in the treatment of antineutrophil cytoplasmic autoantibody-(ANCA) associated vasculitis (AAV) with severe renal involvement. Fifteen AAV patients who had severe renal failure (median SCr 5.6(IQR 5.2-9.0) mg/dL) and needed initial renal replacement therapy (RRT) were treated with DFPP and immunosuppressive therapy. Two plasma volumes were processed during each DFPP session. The changes of serum ANCA and renal function were investigated. After the DFPP treatment for three to five sessions, serum MPO-ANCA level decreased from 250.0 +/- 86.9 RU/mL to 70.5 +/- 64.7RU/mL (P=0.00), with a median reduction rate of 67.6%. Eleven patients (73.3%) no longer needed from RRT 3months after DFPP treatment, while another four patients remained on dialysis. During the follow up for median 10 (IQR 6-24) months, SCr level decreased to normal in one patient, one patient progressed into ESRD. The 1year renal survival rate was 62.9%. Five (33.3%) patients were complicated with pulmonary infection. DFPP combined with immunosuppressive therapy could increase the renal recovery rate through rapidly decreasing serum ANCA levels for AAV patients with severe renal failure, but its clinical efficacy and impact on long-term renal survival require further studies.
机译:我们的目的是研究双过滤血浆置换术(DFPP)在严重肾脏受累的抗中性粒细胞胞浆自身抗体(ANCA)相关血管炎(AAV)的治疗中的临床疗效。 15例严重肾功能衰竭(中位SCr 5.6(IQR 5.2-9.0)mg / dL)并需要初始肾脏替代治疗(RRT)的AAV患者接受DFPP和免疫抑制治疗。在每个DFPP会话期间处理了两个血浆体积。调查血清ANCA和肾功能的变化。在DFPP治疗三到五个疗程后,血清MPO-ANCA水平从250.0 +/- 86.9 RU / mL降低至70.5 +/- 64.7RU / mL(P = 0.00),中位降低率为67.6%。 DFPP治疗后3个月,不再需要RRT的11例患者(占73.3%),而另外4例仍在接受透析。在中位10(IQR 6-24)个月的随访中,一名患者的SCr水平降至正常,一名患者进入ESRD。 1年肾脏存活率为62.9%。五例(33.3%)并发肺部感染。 DFPP联合免疫抑制疗法可通过迅速降低严重肾功能衰竭AAV患者的血清ANCA水平来提高肾脏恢复率,但其临床疗效和对长期肾脏生存的影响尚需进一步研究。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号